Ken Kengatharan is currently a co-founder and Chairman of Renexxion, and Managing Director at Atheneos Capital, an evergreen healthcare incubator fund going forward focusing on opportunities in orphan drugs and rare diseases. He is a co-founder and former President & CEO of Armetheon and a co-founder and former President & CSO of Altheos, and a co-founder and former Vice President, Pre-Clinical R&D of Athenagen (re-named CoMentis).
During the last 17 years, Ken has been critical to the development of multiple drug candidates (NCEs and re-purposed drugs) from concept to Phase II/III. Since setting-up his fi rst company in the late 1990s, working with a great team in each case, Ken has been instrumental in raising more than $160 MM in private equity for seven start-up companies and for closing partnership transactions in excess of $800M in deal value. He is currently a board member at Armetheon and at Renexxion, a venture advisor at SPIRE BioVentures, and an advisor to Stanford University’s SPARK program. He has served on the boards of EPi3 (UK), Athenagen and Altheos, been an advisory board member at Cardinal Free Clinics (Stanford University School of Medicine), a mentor at University of California, San Francisco (UCSF)’s entrepreneurship program and a panel judge for the Stanford Business School’s Ignite Program.
Ken Kengatharan obtained his PhD in pharmacology from the University of London at the William Harvey Research Institute under the supervision of Nobel laureate Sir John Vane and Professor Christoph Thiemermann. Thereafter, he held a post-doctoral position at the same institute as a recipient of a British Heart Foundation Fellowship. He obtained his MBA (with Distinction) from Durham University in England, where he focused on Biotech Finance and Entrepreneurship.
Since 2016, Ken Kengatharan has been an advisor and co-chair of PGE’s Orphan Drugs & Rare Diseases Global Congress held in Europe and in the United States.